-
Product Insights
NewSquamous Non-Small Cell Lung Cancer – Drugs In Development, 2024
Empower your strategies with our Squamous Non-Small Cell Lung Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Squamous cell carcinoma is a subtype of non-small cell lung cancer (NSCLC) originating in the squamous cells lining the airways. It constitutes about 25-30% of all lung cancers. Linked to smoking, symptoms include persistent cough, chest pain, and breathing difficulties. Diagnosis involves imaging, biopsy, and staging to determine the cancer's extent. Treatment options depend on the stage but may...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Izuforant in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Izuforant in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Izuforant in Atopic Dermatitis (Atopic Eczema)Drug Details:Izuforant is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SPYK-04 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPYK-04 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SPYK-04 in Non-Small Cell Lung Cancer Drug Details:SPYK-04 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLC-0111 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLC-0111 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SLC-0111 in Pancreatic Ductal AdenocarcinomaDrug Details:SLC-0111 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olezarsen Sodium in Atherosclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olezarsen Sodium in Atherosclerosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olezarsen sodium in Atherosclerosis Drug Details: AKCEA-APOCIIILRx is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Safimaltib in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Safimaltib in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Safimaltib in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XZB-0004 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XZB-0004 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XZB-0004 in Non-Small Cell Lung Cancer Drug Details: SLC-391 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XZB-0004 in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XZB-0004 in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XZB-0004 in Squamous Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XZB-0004 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XZB-0004 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XZB-0004 in Solid Tumor Drug Details: SLC-391 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XZB-0004 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XZB-0004 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XZB-0004 in Acute Myelocytic Leukemia (AML,...